← all works
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- Annals of the Rheumatic Diseases
- Topic
- Rheumatoid Arthritis Research and Therapies
- Field
- Medicine
- Canadian institutions
- Western University
- Funders
- MedacNational Institute for Health and Care ResearchEuropean League Against RheumatismBiogenGilead SciencesSanofiAmgenPfizerEli Lilly and Company
- Keywords
- MedicineAntirheumatic drugsRheumatoid arthritisAntirheumatic AgentsArthritisHydroxychloroquineDiseaseBiological drugsIntensive care medicineImmunologyInternal medicine
- Has abstract in OpenAlex
- no